NYU BIOMARKER CLINICAL AND EPIDEMIOLOGIC CENTER FOR CANCER

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。肺癌是美国癌症死亡的主要原因。纽约大学临床和流行病学中心癌症早期检测的总体目标是发展和前瞻性跟踪大量地理上分散的不同环境癌症风险的前和活跃工会成员，以确定肿瘤前细胞变化和病变，并检测早期癌症。纽约大学的人群将由许多有吸烟史和/或工作场所暴露的人组成。他们将从建筑工会中抽选，在这些工会中，过去接触石棉的工人通常是公用事业工人、石棉绝缘体工人、锅炉工人、钣金工人、木匠和管道安装工。纽约大学中心将获得一份分包合同，以筛查与德克萨斯州核武器设施有关的现役和退役工人。纽约大学临床和流行病学中心将促进招募和抽样大量高风险的蓝领工人，并对p53和K-ras基因上的dna加合物进行分析，对周期蛋白-周期蛋白依赖性激酶进行调节，对信号传导和Rb通路进行调节，以及对癌基因和肿瘤抑制基因进行其他生物分析，将在最早和最可治疗的阶段检测出肿瘤前状况或癌症。荧光支气管镜检查将对某些高风险个体进行支气管刷和粘膜活检，以评估细胞周期失调。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Lung cancer is the leading cause of cancer death in the US. The overall goal of the NYU Clinical and Epidemiologic Center for the Early Detection of Cancer is to develop and prospectively follow large, geographically dispersed populations of former and active union members of varying environmental cancer risk, to identify preneoplastic cellular changes and lesions, and to detect early cancers. The NYU population will consist of many individuals with a history of smoking and/or workplace exposures. They will be drawn from the building trade unions, where past exposure to asbestos was common among utility workers, asbestos insulators, boilermakers, sheet-metal workers, carpenters, and pipefitters. The NYU Center will have a subcontract to screen active and former workers associated with a nuclear weapons facility in Texas. The NYU Clinical and Epidemiologic Center will facilitate recruitment and sampling of a large cohort of high-risk, blue- collarn workers and that assays for DNA-adducts on p53 and K-ras genes, deregulation of the cyclin-cyclin dependent kinases, deregulation of signaling and Rb pathways, and other bioassays for oncogenes and tumor suppressor genes will detect preneoplastic conditions or cancer in the earliest and most treatable stages. Fluorescence bronchoscopy will be performed on certain high risk individuals for bronchial brush and mucosal biopsies to evaluate cell-cycle deregulation.